This session began with Y. Setiady (ImmunoGen, USA) presenting the “Development of IMGN853, a folate receptor α (FRα) targeting antibody-drug conjugate (ADC), for ovarian cancer treatment”. The gene discussed is FOLR1; the disease is ovarian carcinoma.